On February 2, 2022 IDP Pharma, reported that in collaboration with Carlos III Research Institute (ISCIII) and Hospital 12 de Octubre in Madrid, has published a study in the journal Neurotherapeutics (View Source) which reveals that a new experimental drug, IDP-410, directly engages the key oncoprotein N-MYC and reduces the growth of glioblastomas in animal models (Press release, IDP Pharma, FEB 2, 2022, View Source;utm_medium=rss&utm_campaign=a-novel-therapeutic-peptide-that-alters-n-myc-stability-and-reduces-angiogenesis-and-tumor-progression-in-glioblastomas [SID1234607763]). The Company expects to develop further IDP-410 to bring a novel therapy to patients which currently lack treatment options.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!